Streetbeat News

Regulatory

ARGX

ZLAB

argenx and Zai Lab have received approval from China's NMPA for VYVGART Hytrulo, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This marks the first and only NMPA-approved treatment for CIDP in China.

Portfolio Pulse from

November 11, 2024 | 12:45 pm

CMCSA

The article discusses the potential impact of Trump's second term on high-yield dividend telecom stocks, suggesting that fewer regulations could benefit these stocks.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

NVDA

The article discusses potential factors that could negatively impact Nvidia's stock price. It highlights concerns about market saturation, competition, and potential regulatory challenges that could drive Nvidia's stock down.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

TECH

Bio-Techne Corporation has achieved IVDR certification for its R&D Systems Hematology Controls and Calibrators, ensuring compliance with EU regulations for in-vitro diagnostic devices.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

CANF

Can-Fite BioPharma Ltd. has dosed the first patient in its Phase IIa clinical trial for advanced pancreatic adenocarcinoma, following the recent Orphan Drug Designation by the US FDA.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

BEN

Franklin Resources, Inc. is under investigation by Levi & Korsinsky for potential securities law violations. The investigation follows a Wells Notice received by Ken Leech, co-Chief Investment Officer of its subsidiary, Western Asset Management Company.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

AVXL

SAVA

The article discusses the effectiveness of Panax ginseng, Anavex's Blarcamesine, and Cassava Sciences' Simufilam in treating Alzheimer's disease. Panax ginseng shows the highest effectiveness, while Anavex's Blarcamesine may slow progression in mild cases. Cassava Sciences' Simufilam shows limited effectiveness.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

UNCY

Unicycive Therapeutics announced that the FDA has accepted their NDA for Oxylanthanum Carbonate, a treatment for hyperphosphatemia in dialysis patients, with a PDUFA date set for June 28, 2025. The company is preparing for a commercial launch in 2025.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

TSCDY

Shore Capital analysts predict Tesco PLC will face a £250 million increase in costs due to tax hikes in the recent Budget, following Asda's warning of price hikes.

Portfolio Pulse from

November 11, 2024 | 11:30 am

LPHM

Gan & Lee Pharmaceuticals presented Phase 2b clinical data for GZR18 injection at ObesityWeek®️ 2024, showing significant weight loss in overweight and obese adults. The study found comparable efficacy and safety between bi-weekly 48 mg and once-weekly 24 mg doses.

Portfolio Pulse from

November 11, 2024 | 11:30 am